Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...

Bank of America Securities analyst Alec Stranahan reiterated a Hold rating on Moderna (MRNA – Research Report) today and set a price ...

Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed ...

Moderna earned $5.4 billion in U.S. revenues in 2021 and $4.4 billion in 2022 from COVID-19 vaccine sales. Northwestern University’s nanotechnology research institute, IIN, has supported over $2 ...

Northwestern University filed a patent infringement lawsuit this week against Moderna, alleging the Cambridge, Mass.-based drugmaker used patented vaccine-delivery technology developed by ...

Shares up nearly 5% to $54.22 in early trading Spikevax COVID vaccine sales reached $1.8 billion, beating expectations Moderna expects lower COVID vaccine sales this year compared to 2023 $10 ...

In an interview with NBC News, the former president also said a push by RFK Jr. to remove fluoride in water “sounds OK to me.